Sanity Group, a Berlin, Germany-based healthcare company focused on cannabinoids and the endocannabinoid system, raised $37.6M in Series B funding.
The round, which brings brings total funds raised to date to over $100m, was led by BAT Group with participation from Will.I.Am, Alyssa Milano, Scooter Braun, Redalpine, Casa Verde Capital, HV Capital, Calyx, TQ Ventures, Atlantic Food Labs, Cherry Ventures, Bitburger Ventures, SevenVentures, GMPVC, Navy Capital and SOJE Capital.
The company intends to use the funds to accelerate its growth, enable European expansion and strengthen research and development activities.
Led by CEO Finn Age Hänsel, Sanity Group aims to improve people’s quality of life through the use of cannabinoids and the endocannabinoid system. In addition to pharmaceuticals, the company’s focus is also on wellbeing and cosmetic products that utilize cannabinoids. Founded in Berlin in 2018 by Finn Age Hänsel and Fabian Friede, Sanity Group includes Vayamed and AVAAY Medical (medicinal cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), Belfry Medical (medical products and digital applications), VAAY (wellbeing) and This Place (natural cosmetics). Sanity Group also operates a production and processing facility for cannabis extracts near Frankfurt am Main.
The company has around 120 employees in the medical, consumer health and science sectors.
FinSMEs
26/09/2022